Alto Neuroscience logo

Alto Neuroscience

ANRO | NYSE
Chart Builder DCF Calculator
$27.12
-$2.42 (-8.19%)
At close: Nov 16, 2026, 4:00 PM ET
$27.12
$0.00 (0.00%)
After-hours: Nov 16, 2026, 4:01 PM ET
-8.19%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
33.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #696/1021 (Top 68%)

Key Statistics

Market Data

Market Cap $1.26B
1D Range
26.94 29.54
52W Range
12.80 36.64

Valuation (TTM)

PE -10.85
PB 4.26
EV/EBITDA -10.49

Valuation (NTM)

Forward PE N/A
Forward PEG -0.93
Price Target $37.00
Loading financial charts...

Profile

Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an inve...

Sector Healthcare
Industry Biotechnology
Employees 68
IPO Date Feb 2, 2024
Fiscal Year January - December

Latest News

Alto Neuroscience, Inc. (ANRO) Upgraded to Buy: Here's What You Should Know

13 hours ago · zacks.com

Alto Neuroscience, Inc. (ANRO) Upgraded to Buy: Here's What You Should Know
Wall Street Analysts Predict a 29.38% Upside in Alto Neuroscience, Inc. (ANRO): Here's What You Should Know

15 hours ago · zacks.com

Wall Street Analysts Predict a 29.38% Upside in Alto Neuroscience, Inc. (ANRO): Here's What You Should Know
Alto Neuroscience Announces Participation in Upcoming Investor Conferences

2 months ago · businesswire.com

Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

3 months ago · businesswire.com

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

Analyst Summary

# of Analysts
7
Consensus
Buy
Price Target
$37.00
Upside
+36.43%
Buy (6)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.